Sponsor: Rubicon Genomics
Recording Date: 2/19/2014
Recording Time: 1 hour
As the Account Executive – Urology, you will be responsible for increasing the number of Prolaris test orders sent to Myriad in your assigned territory. This is accomplished by focusing on 30-50 urologists, urologic oncologists, and affiliated pathologists practicing in 1-2 metropolitan areas. The successful Account Executive will gain a deep understanding of their assigned physician practices and utilize that understanding to offer new insights to their customers that challenge the current prostate cancer risk assessment paradigm. Specifically, high-performing Account Executives will grow their weekly order volumes by teaching, tailoring, and taking control of customer conversations in community, large group, and academic practice settings. Key competencies include the ability to offer unique perspectives to customers, drive two-way communication with targeted physicians, learn and understand practice value and economic drivers, and influence customers to take action they would not have taken otherwise.
* Meet with all top 30-50 franchise accounts at least 2 times per month
* Identify and implement an action plan to drive growth in territory
* Focus majority of resources towards targeted physicians
The clinical challenge facing physicians and their patients newly diagnosed with prostate cancer is whether to choose definitive therapy such as surgery or radiation, which have potentially significant complications, or to monitor the patient’s cancer through active surveillance or watchful waiting. Unfortunately, existing clinical parameters (PSA, Gleason score, and stage) used to make this difficult decision do not adequately predict which cancers are indolent or aggressive, resulting in both under treatment and overtreatment of men with prostate cancer. Myriad Genetic Laboratories discovered and validated Prolaris®, a novel RNA expression-based prognostic test, to fulfil this pressing unmet clinical need. Prolaris directly measures tumor cell growth characteristics in order to stratify patients with localized prostate cancer according to disease aggressiveness. More than 700 urologists and urologic oncologists in the U.S. have used the test to identify both low-risk patients who may be monitored through active surveillance or watchful waiting, as well as high-risk patients who may benefit from earlier definitive treatment. Prolaris is the only molecular test in its category with 6 peer-reviewed publications supporting its clinical validity and two forthcoming publications that demonstrate significant change in treatment selections as a result of the test.
* BS/BA degree and minimum of two years of sales experience, preferably in medical device, pharmaceuticals, or related healthcare services
* Able to work independently with strong work ethic
* Must demonstrate a high level of scientific/medical knowledge
* Must be willing to travel to appointments throughout the territory with occasional overnight responsibilities
* Urology experience is desired but not required
Apply Here: http://www.Click2Apply.net/n2jqsyn